Trial Profile
An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 04 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
- 04 Mar 2015 Planned initiation date changed from 1 Mar 2014 to 1 Mar 2015, as reported by ClinicalTrials.gov.